

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2007

AVENTIS PHARMA LIMITED

Registered Office: Aventis House, 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 31.03.2007 (Reviewed)	Quarter ended 31.03.2006 (Reviewed)	Year ended 31.12.2006 (Audited)
1 Sales	2,265	2,119	9,367
Less : Excise duty recovered	136	114	527
Sales (Net)	2,129	2,005	8,840
2 (a) Other Income	105	56	194
(b) Interest and Dividend Income	95	40	277
3 Total Expenditure			
(a) (Increase)/Decrease in Stock in trade	(228)	(238)	(225)
(b) Materials	1,262	1,198	4,511
(c) Staff Cost	210	179	785
(d) Other Expenditure	391	374	1,562
4 Interest	-	-	2
5 Depreciation	45	43	179

Particulars	Quarter ended 31.03.2007 (Reviewed)	Quarter ended 31.03.2006 (Reviewed)	Year ended 31.12.2006 (Audited)
6 Profit Before Tax	649	545	2,497
7 Provision for Taxation			
- Current	190	180	838
- Deferred	17	(12)	(74)
- Fringe benefit tax	9	8	40
8 Net Profit	433	369	1,693
9 Paid-up Equity Capital (Face Value Rs. 10 per Share)	230	230	230
10 Reserves excluding Revaluation Reserves	-	-	5,656
11 Earnings per Share (Rs.) (not annualised)	18,83	16,04	73,51
12 Aggregate of Non- Promoter Shareholding			
- Number of Shares	9,120,955	9,125,820	9,120,955
- Percentage of Shareholding	39.60	39.62	39.60

Notes:

- The above Results were approved by the Board of Directors of the Company at its Meeting held on April 16, 2007.
- The break up of Net Sales is as follows:

	Quarter ended March 31, 2007	Quarter ended March 31, 2006	Growth %
Domestic Sales	1,706	1,535	11.1%

	Quarter ended March 31, 2007	Quarter ended March 31, 2006	Growth %
Export Sales	423	470	-10,0%
Total Sales	2,129	2,005	6.2%

- Other Income for the quarter ended March 31, 2007 includes write back of excess provision for indirect tax amounting to Rs 50 million.
- Effect of Accounting Standard 15 (Revised) (AS 15) Employee Benefits for the quarter ended March 31, 2007 has been considered in the above and additional impact, if any as at the beginning of the year will be adjusted from the Reserves and Surplus as per transitional provisions of AS 15.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2007.
- The Board of Directors had, at its Meeting held on March 16, 2007 declared a Second Interim Dividend of Rs. 28.50 per Equity Share of Rs. 10 (inclusive of a Special One-time Golden Jubilee Dividend of Rs.16.00 per Equity Share of Rs.10 to commemorate the completion of fifty years of the Company which was incorporated in May 1956) for the year ended December 31, 2006. The said Second Interim Dividend has been paid in March 2007.
- The Register of Members and Share Transfer Books of the Company will be closed from June 5, 2007 to June 15, 2007 (both days inclusive) for the purpose of the Annual General Meeting.
- Information on investor complaints is furnished below:

Pending as on January 1, 2007	Received during the quarter	Disposed of during the quarter	Pending as on March 31, 2007
2	1	2	1

- The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED
DR. SHAILESH AYYANGAR
MANAGING DIRECTOR